Compare BioNano Genomics Inc (BNGO) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Vistra Corp — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Vistra Corp trades at $146.69 (market cap $48.64B). The key difference: Vistra Corp is far larger — about 3560.8× BioNano Genomics Inc's market cap, and Vistra Corp pays a 0.63% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | VST | |
|---|---|---|
Market Cap | $13.66M | $48.64B |
Sector | Health | Technology |
52-Week High | $4.92 | $217.92 |
52-Week Low | $1.06 | $134.71 |
Enterprise Value | $16.26M | $70.58B |
Dividend Yield | — | 0.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Vistra (VST) trades at $146.68, up 2.67% today, with a bearish technical signal from moving averages but strong analyst support (90.9% buy ratings). Recent Q2 2026 earnings showed a beat on EPS ($2.87 actual vs. $1.32 expected) but a revenue miss, while the company reaffirmed full-year guidance amid growing data center power demand. The stock's valuation includes a P/E of 24.44 and a high ROE of 75.73%, though net cash flow was negative in 2025.
The outlook is positive due to robust EBITDA growth and strategic positioning in the AI power sector, with a consensus price target of $239.75 implying significant upside. Key risks include ERCOT market volatility, hedging losses, and high debt levels, requiring monitoring of execution on data center deals and cost controls.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
